When is the urethral lift (Urolift) indicated for men with benign prostatic hyperplasia?

Prostatic Urethral Lift (UroLift) Indications for BPH

The prostatic urethral lift (UroLift) is indicated for men with moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia who have lateral lobe obstruction, prostate volume 30-80 cc, and desire preservation of sexual function while accepting potentially higher retreatment rates compared to traditional surgery.

Patient Selection Criteria

Symptom Severity and Baseline Parameters

• IPSS ≥13 with bothersome symptoms and quality of life impairment 1, 2
• Maximum urinary flow rate (Qmax) ≤12 ml/second demonstrating objective obstruction 1
• Prostate volume 30-80 cc based on FDA approval criteria, though emerging evidence suggests efficacy in larger prostates up to 254 g 3, 1

Anatomical Requirements

• Lateral lobe prostatic obstruction is the primary indication 1, 4
• Obstructive median lobes can be treated with UroLift, contrary to earlier restrictions, with controlled trial data showing equivalent outcomes to lateral lobe treatment 5
• Patients with median lobes may benefit from concurrent resection of the median lobe at time of UroLift placement 3

Clinical Advantages Supporting Use

Sexual Function Preservation

• Zero incidence of de novo erectile or ejaculatory dysfunction in controlled trials through 5-year follow-up 1, 2
• This represents a critical advantage over TURP and other ablative procedures 2

Rapid Recovery Profile

• Return to preoperative physical activity within 8.6 days on average 2
• Symptom improvement evident by 2 weeks post-procedure 2
• Can be performed under local anesthesia, avoiding general anesthesia risks 1, 4

Efficacy Outcomes

• IPSS reduction of 11.1 points at 3 months (88% greater improvement than sham control) 2
• Qmax improvement of 4.4 ml/second sustained through 12 months 1
• Durable improvements maintained through 5 years: 36% IPSS improvement, 50% QOL improvement 2

Important Limitations and Caveats

Retreatment Considerations

• Surgical retreatment rate of 13.6% over 5 years in controlled trials 2
• Real-world data shows failure rates of 17.18% requiring other BPH interventions at 2 years 6
• This is higher than TURP but acceptable given the favorable safety profile 4

Comparative Effectiveness

• Flow rate improvements are more moderate than TURP or HoLEP 7
• However, symptom improvement and quality of life gains are comparable to TURP at 1 and 3 months 5

Postoperative Complications

• Acute urinary retention occurs in approximately 7.8% of patients requiring short-term catheterization 6
• Most adverse events are mild to moderate and transient 1, 2
• When catheterization is needed post-procedure, 52.94% achieve successful trial without catheter in less than 7 days 6

Specific Clinical Scenarios

Patients on Anticoagulation

• UroLift is particularly attractive for patients with ongoing anticoagulation or relevant comorbidities given lower periprocedural bleeding risk compared to resective procedures 7

Large Prostate Volumes

• While FDA approval specifies <80 cc, real-world experience demonstrates benefit in prostates >80 cc (up to 254 g) 3
• Larger prostates require more implants (median 4 clips, range 2-8) 6

Anesthesia Options

• 64% of procedures performed under general anesthesia, with regional, local, or entonox as alternatives 6
• This flexibility allows treatment of patients who are poor surgical candidates 4

Contraindications

Anatomical Exclusions

• Central zone obstruction without lateral lobe component is unsuitable 4
• Significant median lobe obstruction may require alternative or adjunctive treatment 3

Patient Expectations

• Patients must understand the permanent implant placement in the prostatic urethra 4
• Higher retreatment rates compared to TURP should be discussed during counseling 6